Classical hemophilia results from a defect of the intrinsic tenase complex, the main factor X (FX) activator. Binding of factor VIIa to tissue factor triggers coagulation, but little amplification of thrombin production occurs. Handling of hemophilia by injection of the deficient or missing (thus foreign) factor often causes immunological complications. Several strategies have been designed to bypass intrinsic tenase complex, but none induce true auto-amplification of thrombin production. In an attempt to re-establish a cyclic amplification of prothrombin activation in the absence of tenase, we prepared a chimera of FX having fibrinopeptide A for the activation domain (FX FpA ). We reasoned that cascade initiation would produce traces of thrombin that would activate FX FpA (contrary to its normal homologue). Given that the activation domain of FX is released upon activation, thrombin cleavage would produce authentic FXa that would produce more thrombin, which in turn would activate more chimeras. Blood clotting results from a cascade of zymogen activation that culminates with a large production of thrombin (1-4). Injury initiates the process by uncovering tissue factor (TF), 3 which captures circulating activated factor VII (FVIIa) to form a complex that activates factors IX (FIX) and X (FX). Traces of activated FX (FXa) are sufficient to produce a small amount of thrombin empowering the cascade to inflate. The two main amplification complexes within this cascade are intrinsic tenase, composed of activated factor VIII (FVIIIa) associated with FIXa, and prothrombinase, composed of activated factor V (FVa) associated with FXa. The former activates FX into FXa, the latter, prothrombin into thrombin. Hemophilias A and B are coagulopathies resulting from a dysfunction of the intrinsic tenase complex, following a defect of FVIII or FIX, respectively (5). As a consequence, there is an inadequate production of FXa and subsequently of thrombin. Despite normal triggering, little amplification of thrombin production occurs. To date, replacement therapy is the only treatment that re-establishes an intrinsic auto-amplification of thrombin production (6). Therapy simply consists of administering the deficient FVIII or FIX. The main drawback of this approach resides in the potential antigenicity of the injected molecule, because it is often seen as foreign by the recipient. Neutralizing allo-antibodies makes replacement therapy gradually ineffective. Three approaches that bypass the intrinsic tenase complex without re-establishing auto-amplification of thrombin formation have been used or envisaged. In the first, injection of a mixture of the vitamin K-dependent factors (FVII, FIX, FX, and prothrombin) effectively bypasses tenase. Treatment however induces rare but serious side effects, including anaphylactic shock and thrombotic incidents. A mixture of recombinant prothrombin and FXa is currently under consideration to improve this approach (7). An efficient alternative relies on supraphysiologic injection of FVIIa (8 -9). Unfortunately, the plasma half-life of FVIIa is less than 3 h (10), thus large amounts are required rendering therapy complicated and tremendously expensive (11). A combination of FVIIa and FX that could lower the cost is under investigation (12). Administration of inhibited FXa that would slowly recover its activity in plasma had also been considered: FXa either in combination with phospholipid vesicles (13, 14) or acetylated (15, 16) . Finally, induction of microparticles through P-selectin stimulation improves the kinetics of fibrin formation in hemophilia A mice (17).
Blood clotting results from a cascade of zymogen activation that culminates with a large production of thrombin (1) (2) (3) (4) . Injury initiates the process by uncovering tissue factor (TF), 3 which captures circulating activated factor VII (FVIIa) to form a complex that activates factors IX (FIX) and X (FX). Traces of activated FX (FXa) are sufficient to produce a small amount of thrombin empowering the cascade to inflate. The two main amplification complexes within this cascade are intrinsic tenase, composed of activated factor VIII (FVIIIa) associated with FIXa, and prothrombinase, composed of activated factor V (FVa) associated with FXa. The former activates FX into FXa, the latter, prothrombin into thrombin. Hemophilias A and B are coagulopathies resulting from a dysfunction of the intrinsic tenase complex, following a defect of FVIII or FIX, respectively (5) . As a consequence, there is an inadequate production of FXa and subsequently of thrombin. Despite normal triggering, little amplification of thrombin production occurs. To date, replacement therapy is the only treatment that re-establishes an intrinsic auto-amplification of thrombin production (6) . Therapy simply consists of administering the deficient FVIII or FIX. The main drawback of this approach resides in the potential antigenicity of the injected molecule, because it is often seen as foreign by the recipient. Neutralizing allo-antibodies makes replacement therapy gradually ineffective. Three approaches that bypass the intrinsic tenase complex without re-establishing auto-amplification of thrombin formation have been used or envisaged. In the first, injection of a mixture of the vitamin K-dependent factors (FVII, FIX, FX, and prothrombin) effectively bypasses tenase. Treatment however induces rare but serious side effects, including anaphylactic shock and thrombotic incidents. A mixture of recombinant prothrombin and FXa is currently under consideration to improve this approach (7) . An efficient alternative relies on supraphysiologic injection of FVIIa (8 -9) . Unfortunately, the plasma half-life of FVIIa is less than 3 h (10), thus large amounts are required rendering therapy complicated and tremendously expensive (11) . A combination of FVIIa and FX that could lower the cost is under investigation (12) . Administration of inhibited FXa that would slowly recover its activity in plasma had also been considered: FXa either in combination with phospholipid vesicles (13, 14) or acetylated (15, 16) . Finally, induction of microparticles through P-selectin stimulation improves the kinetics of fibrin formation in hemophilia A mice (17) .
Activation of FX requires cleavage of the Arg 52 -Ile 53 bond in the heavy chain (Arg 194 -Ile 195 of the cDNA translation), between the activation and pending catalytic domains, the former being released upon cleavage. TF/FVIIa and intrinsic tenase complexes are the only in vivo activators of FX. Thrombin in particular is unable to cleave the Arg 52 -Ile 53 bond of FX (18) . In this study, we describe the preparation and characterization of a thrombin-activable FX chimera (FX FpA ) in which the sequence of fibrinopeptide A (FpA) substitutes for the activation domain of FX. We reasoned that because thrombin rapidly releases FpA from fibrinogen to produce fibrin, the substitution could transpose to FX the high susceptibility of fibrinogen to thrombin. Indeed, FX FpA not only made it possible to bypass tenase, it also re-established an autoamplification of thrombin generation. The activated form of FX FpA being identical to FXa must function normally within prothrombinase to produce thrombin. In turn, thrombin would activate more molecules of FX FpA allowing a cyclic amplification of thrombin production (Fig. 1) .
EXPERIMENTAL PROCEDURES
Proteins and Reagents-Human prothrombin and antithrombin were isolated from outdated plasma, thrombin produced through prothrombin conversion, and phospholipid vesicles prepared, as previously described (18 -20) . Human FIXa, FX, FXa, and FVIIa, bovine FV/FVa, FX activator isolated from the venom of Russell's viper (RVV-X), and heparin were purchased from Kordia (Leiden, The Netherlands). Normal and immunodepleted plasmas were purchased from Diagnostica Stago (Asnières-sur-Seine, France). Recombinant FVIII was from Baxter (Lessines, Belgium), hirudin (Refludan) from Hoechst (Frankfurt, Germany), and recombinant TF from Dade Behring (La Défense, France). Platelet Factor 3 reagent (PF3) was purchased from Organon Teknika. Gly-Pro-Arg-Pro-amide peptide, Phenylmethylsulfonyl fluoride (PMSF), Polybrene, and bovine serum albumin (BSA, proteasefree) were purchased from Sigma-Aldrich. H-D-Phe-Pip-Arg-pNA (S2238), Z-D-Arg-Gly-Arg-pNA (S2765), and benzoyl-Ile-Glu(␥-OR)-Gly-Arg-pNA (S2222) were obtained from Biogenic (Maurin, France); H-D-Phe-Phe-Arg-CH 2 Cl (PPACK2) from VWR International (Fontenay-sous-Bois, France).
Preparation of Recombinant Human FX and Derivatives-The shuttle vector pNUT-FX (21) carrying the cDNA coding for the propeptide of human prothrombin in place of that of FX and with amino acids DQVDPRLIDGK (recognized by monoclonal antibody HPC-4 (Roche Applied Science) at the 3Ј-end) was used as a template to prepare the vector expressing FX FpA . Constructions were prepared through a single polymerase chain reaction, and sequence coding for FX FpA was verified by dideoxy chain termination, as previously described (21) . Selection of transfected BHK-21 cells and production of FX FpA were also achieved as previously described (19, 22, 23) . Milligram quantities of FX FpA were initially purified by a combination of anion exchange and affinity (using HPC-4 antibody coupled to agarose) chromatography, as described for production of prothrombin derivatives (22) . Final recombinant products (FX and FX FpA ) appeared homogeneous by Coomassie Blue staining following SDS-polyacrylamide gel electrophoresis. However, part of the preparation with an apparent molecular mass of 66 kDa was unaffected by incubation with ␤-mercaptoethanol, suggesting that recombinant protein was incompletely processed, probably secreted as a single chain precursor that was weakly ␥-carboxylated (Fig. 2) . Therefore, an additional purification step was introduced to separate fully processed FX FpA by hydroxyapatite chromatography (24, 25) . Briefly, concentrate obtained by anion exchange chromatography on QAE-Sephadex A50 was precipitated by 80% saturation (NH 4 ) 2 SO 4 and resuspended in 10 mM NaH 2 PO 4 /Na 2 HPO 4 pH 6.5. Redissolved proteins were loaded onto a hydroxyapatite column equilibrated in the same buffer, which was developed by a 10-volume linear gradient of up to 0.5 M NaH 2 PO 4 / Na 2 HPO 4 , pH 6.5. Fully processed and ␥-carboxylated FX was eluted in the late peak as reported by Larson et al. (24) . Following dilution of 1:10 (v/v) in water, the buffer was exchanged to Tris (50 mM, pH 7.5) containing 500 mM NaCl by anion exchange chromatography onto a Q-Sepharose Fast Flow column (Amersham Biosciences). Calcium concentration was adjusted to 5 mM, and recombinant FX was purified by affinity chromatography as previously described (21 (23). Large quantities of activated FX FpA were prepared by passage through a 1-ml HiTrap N-hydroxysuccinimide-activated column coupled to thrombin (1 mg/ml of gel) according to the manufacturer's instructions. 4 mg of zymogen in kinetic buffer without BSA were continuously passed through the column at 0.5 ml/min for 16 h at 25°C. Following activation, FXa and the activated form of FX FpA were purified by chromatography on a heparinSepharose column (Amersham Biosciences), and their active site content determined by titration with PPACK2 as previously described (23) . Prior to use, dilution of FXa and activated FX FpA were systematically controlled by measuring the rate of 200 M S2765 hydrolysis. Values of k cat and K m of S2222 and S2765 for FXa and activated FX FpA were estimated by standard methods, as previously described (19, 26) . FXa and Activated FX FpA Inhibition Kinetics-The overall rate of association (k a ) for the inhibition of FXa or the activated form of FX FpA by PPACK2 was estimated in kinetic buffer at 25°C as previously described (20, 26) . Progress of inhibition by antithrombin was studied at 25°C in kinetic buffer containing one unit/ml heparin or 5 g/ml Polybrene. Reactions, carried out in microplates in a volume of 200 l, were initiated by adding 0.5 nM FXa or activated FX FpA to a mixture of antithrombin and heparin or Polybrene. Antithrombin concentration (3 and 6 nM in the presence of heparin; 0.5 and 1.0 M with Polybrene) was such that significant inhibition of the enzyme occurred over the time of experiment (less than 20 min). The substrate concentration (S2765; 200 M) was such that less than 10% was hydrolyzed within 20 min without inhibitor. Observed rates of inhibition (k obs ) were estimated by nonlinear regression analysis of A 405 versus time using Equation 1 for slowbinding inhibition as previously described (20, 26) ,
in which A 405 (0) and A 405 (t) represent A 405 initial (before addition of FXa) and at time t, respectively; v i and v s the initial and final rates of S2765 hydrolysis, respectively (v s is normally zero with serpins). The value of k a was deduced from k obs using Equation 2 to account for the competition introduced by the substrate,
in which S 0 is the initial S2765 concentration, K m , its Michaelis constant for FXa (or activated form of FX FpA ) and I 0 the active concentration of added serpin, estimated as previously described (21) .
Plasma (ex Vivo) Studies of FXa and Activated FX FpA -The half-life in citrated human plasma was estimated by adding 20% (v/v) kinetic buffer containing 40 mM CaCl 2 , 400 units/ml hirudin, and 50 nM FXa (or the activated form of FX FpA ). At timed intervals, aliquots were withdrawn and residual activity estimated from the rate of hydrolysis of 200 M S2765. Observed rates of inhibition (k obs ) were estimated by nonlinear regression analysis of the residual FXa activity with time using a first-order decay equation. Half-life values were calculated by dividing ln(2) by k obs (21) . The anti-hemophilic potential of FX FpA was evaluated by its ability to shorten clotting time and increase thrombin formation in normal FVIII-and FIX-deficient plasmas. Particular care was taken to verify that FXa or activated FX FpA was undetectable prior to addition of their zymogen to plasma. The progress of clot formation was recorded at 37°C by turbidity measurement. 100 l of prewarmed plasma were added to a mixture of 10 l of PF3 and 90 l of kinetic buffer containing 40 mM CaCl 2 , and various amounts of either FX FpA , FX, FXa, FVIIa FVIII, or FIX in a prewarmed microplate. A 405 was recorded every second, and time required to reach half-maximal turbidity was taken as representative of the clotting time. The procoagulant potential of FX and FX FpA was also evaluated by its ability to induce thrombin formation in normal, FVIII-or FIX-depleted plasma. Clotting was triggered at 37°C by adding 50% (v/v) kinetic buffer containing 40 mM CaCl 2 , 160 M phospholipid vesicles, 0.5 nM TF, and various amount of FVIIa, FVIII, FIX, FX, or FX FpA to prewarmed plasma containing 16 mM GlyPro-Arg-Pro-amide to prevent fibrin polymerization (27) . At timed intervals, aliquots were withdrawn, and reactions quenched by diluting samples (1:10, v/v) in Tris, 50 mM; NaCl, 150 mM; pH 8.0 containing 10 mM EDTA, and 100 mM benzamidine. The amount of thrombin was monitored from the rate of 100 M S2238 hydrolysis after further dilution (1:20, v/v) in kinetic buffer without BSA (21) .
RESULTS
Thrombin Activates FX FpA -Thrombin specificity originates in part from amino acids framing the arginine preceding the bond cleaved within substrates (18, 23) , but complementary secondary sites also contribute critically to binding of the major ligands, including fibrinogen (28 -30) . In conjunction with the 60-loop insertion of thrombin, the aryl binding site provides a remarkable niche for FpA of fibrinogen (22, 28, (31) (32) (33) (34) . To test if simple substitution for FpA of the activation peptide of FX would permit thrombin cleavage, we prepared a chimera (FX FpA ) in which amino acids DFLAEGGGVR replaced the entire activation domain of FX (from Ser 1 to Arg 52 of the heavy chain). FX FpA was produced in BHK-21 cells, and a fraction fully processed and ␥-carboxylated was purified to homogeneity by a combination of anion exchange, hydroxyapatite, and affinity chromatography. As anticipated, incubation of chimera with thrombin resulted in the development of FXa-like activity, whereas prolonged incubation of FX with thrombin remained without effect (Fig. 3) . Estimates of 5.9 Ϯ 0.3 ϫ 10 Ϫ3 s Ϫ1 for k cat and 1.4 Ϯ 0.2 M for K m were obtained through Michaelis-Menten kinetics (Fig. 4) , and of 4.
first-order kinetics (Fig. 3) (Fig. 3) . Surprisingly, activation rates of FX FpA and FX by TF-FVIIa were comparable, as were the activation rates by RVV-X. That the mutation had little impact on the interaction of FX with TFFVIIa or RVV-X was consistent with the overall folding being preserved. Partial deletion in FX of the activation domain has little influence on the activation by RVV-X or the TF-FVIIa complex, yet it dramatically affects activation by the FVIIIa-FIXa complex (36 -38). Rudolph et al. (39) , however, have shown that when an FX precursor lacking its activation domain is expressed as a single chain precursor, activation by RVV-X is impeded as is that by TF-FVIIa. Thus, rather than the presence of the activation domain itself, processing and folding seems critical for FX activation. In favor of a limited function, none of the 41 deleterious mutations reported for FX are located in its activation domain (40) . FX FpA Releases Authentic FXa upon Activation-Conceptually, FX FpA was designed to release normal FXa upon cleavage by thrombin given that FpA would be freed after activation. To verify this assumption, we compared FXa obtained through FX activation by RVV-X with activated FX FpA produced by thrombin cleavage. Large quantities of FXa were prepared by passage of FX through a column linked with RVV-X and large quantities of the activated form of FX FpA by passage of FX FpA through a column linked with thrombin. Activation products were concentrated by heparin-Sepharose chromatography, and their active site concentration was determined. Following SDS-PAGE analysis, apparent molecular masses for the heavy and light chains of the activation products from FX and FX FpA were indistinguishable (Fig. 2) . Activation products were transferred onto polyvinylidene difluoride membranes, and N-terminal sequence of the heavy chain was determined. IVGGQ was obtained for the activated form of FX FpA , which corresponded unambiguously to that of FXa issuing from a cleavage between the P 1 and P 1 Ј residues of normal FX. Next, we compared S2222 and S2765 as substrates, and PPACK2 as an inhibitor for FXa and activated FX FpA . Values of k cat , K m , and k a were obtained suggesting that signatures of the proteases were hardly discernible (TABLES ONE and TWO). We also verified that FXa produced through FX or FX FpA activation were neutralized by antithrombin with comparable k a values (Fig.  5) . Finally, the half-life in the plasma of FXa produced through FX or FX FpA activation were similar suggesting again full interchangeability between the two molecules (Fig. 6) .
FX FpA Corrects Clotting Time of FVIII-or FIX-deficient Plasmas-
One of the difficulties we encountered in testing anti-hemophilic potential of our thrombin-activable FX was that even traces of FXa shorten the clotting time of FVIII-or FIX-deficient plasmas. As little as 15 pM FXa appreciably decreased the time to clot formation, whereas 250 pM FXa reduced the clotting time to a value comparable to that obtained with normal plasma. Adding FXa to normal plasma also shortened its clotting time (Fig. 7) , allowing detection of minute FXa contamination. Thus, it was of utmost importance to ascertain that our FX FpA preparation was exclusively in a zymogen form and devoid of FXa contamination. To this aim, FX FpA was treated twice for 30 min with PPACK2 and separated from excess PPACK2 by (NH 4 ) 2 SO 4 precipitation. Amidolytic activity of PPACK2-treated FX FpA was undetectable. FX FpA prepared as above had no detectable influence on the clotting time of normal plasma, even at concentrations above 100 nM, suggesting that FXa contamination, if any, represented less than 0.01% FX FpA and that excess PPACK2 was properly removed by (NH 4 ) 2 SO 4 precipitation (Fig.  7) . This observation also suggested that FX FpA (as a zymogen) did not interfere with coagulation cascade in normal plasma. This is in contrast to FVIIa and FVIII, which under the same conditions shorten the clotting time when added to normal plasma (Fig. 7) . Interestingly, wild-type FX also slightly decreased the clotting time of normal plasma. Thus FX FpA could be devoid of an overdose effect, a considerable advantage for handling hemophilia. We then compared the effect of increasing amounts of FX FpA on the clotting time of FVIII-or FIX-deficient plasmas. Adding 64 -128 nM FX FpA was sufficient to decrease clotting time to a value comparable to that obtained with normal plasma (Fig. 8) . Addition of 64 -128 nM FVIIa also corrected the clotting time of FVIIIor FIX-deficient plasmas, as well as 50 -100 milliunits of FVIII or 6 -12 nM FIX, respectively (Fig. 8) . It is to mention, however, that adding wild-type FX also shorten the clotting time of FVIII-depleted plasma, albeit not as efficiently as FX FpA (amount of 450 nM were required to apparently correct clotting time). Unfortunately, rather than really informative, these observations simply point out that clotting time assays are insufficient to test the potential of anti-hemophilic factors. That about 100 nM FX FpA was sufficient to correct clotting time in FVIII-or FIX-deficient plasmas was surprising at first, because the k cat /K m value estimated above suggested that, within 3 min, only about 60 pM FXa would be produced through FX FpA activation by 1 nM thrombin. Nevertheless, as already mentioned, addition of 250 pM FXa was sufficient to decrease clotting time of FVIII-or FIX-deficient plasmas to that of a normal plasma. Thus, considering that production of FXa also originated from FX (and FX FpA ) activation by the TF-FVIIa complex, it is conceivable that sufficient amount of FXa was produced to correct clotting time (41, 42) .
FX FpA Amplifies Thrombin Production in FVIII-or FIX-deficient Plasmas-The clotting time of plasma mimicking that of hemophiliacs suggested that in the presence of FX FpA , thrombin was produced in a quantity allowing enough fibrin to be released for clot formation. As little as 10 nM thrombin is sufficient to induce clotting within 3 min in FVIII-depleted plasma. We therefore wondered what amount of thrombin was actually produced through FX FpA activation once the clotting cascade was triggered. To this aim, Gly-Pro-Arg-Pro-amide was added to FVIII-depleted plasma to prevent fibrin polymerization (27, 43) . Use of Ancrod to defibrinate plasma was proscribed, because in addition to hydrolyzing fibrinogen, the snake venom activated rapidly FX FpA carrying FpA in place of its normal activation peptide (data not shown). Thrombin production was triggered in noncoagulable plasmas by adding TF and phospholipid, and aliquots were withdrawn at timed intervals. Activation reactions were quenched and the amount of thrombin estimated through S2238 hydrolysis. Undoubtedly, FX FpA had the potential to correct thrombin generation of FVIII-depleted or FIX-depleted plasmas (Fig. 9) . When 128 nM FX FpA was added, the lag phase and maximum amount of thrombin favorably compared with the amount produced when deficient plasma was supplemented with its missing factor. Therapeutic doses of FVIIa, allowing handling of severe hemophilia, result in a plasma concentration of about 70 nM (44) . Thrombin production of plasma mimicking that of hemophiliacs also improved dramatically when the clotting cascade was triggered in the FIGURE 9. Amplification of thrombin production in FVIII-depleted plasma. The procoagulant effect of FX FpA was evaluated by its ability to increase thrombin production in FVIII-deficient plasma. Graphs represent thrombin concentration as a function of time when the cascade was triggered at 37°C by adding a mixture of phospholipid vesicles, calcium, and TF to FVIII-depleted plasma rendered noncoagulable by addition of GlyPro-Arg-Pro-amide. In both panels, the open circles are results obtained without addition of anti-hemophilic factor. A, thrombin production was evaluated in the presence of increasing amounts of FX FpA (closed circles, 128, 64, 32, 16, 8, 4 , and 2 nM from left to right). B, thrombin production was evaluated in the presence of one unit/ml FVIII (closed squares), 100 nM FXFpA (closed circles), 70 nM FVIIa (open squares), or 100 nM wild-type FX (closed triangles). Thrombin production obtained in the presence of one unit/ml FVIII was comparable to that of normal plasma triggered under the same conditions (without anti-hemophilic factor). FIGURE 8. Clot formation in FVIII-depleted plasma. Graphs represent progress curves of clot formation as in Fig. 7 presence of 70 nm FVIIa, yet the total amount remained below that observed in normal plasma. Finally, whereas wild-type FX shortens clotting time of FVIII-depleted plasma, it influenced thrombin production very little (Fig. 9) .
DISCUSSION
In designing a thrombin-activable FX chimera as an antihemophilic factor, we anticipated several decisive advantages. First, reciprocal activation between thrombin/FX FpA and FXa/prothrombin would re-establish a true auto-amplification of thrombin production. The normal clotting cascade generates more thrombin than is apparently necessary (3), but a minimum amplification is nevertheless required. The rate of thrombin production should locally exceed that of its neutralization by antithrombin to attain rapidly (less than 3 min) a threshold allowing sufficient fibrin production. Because of the conjunction of several mechanisms acting in synergy, supraphysiologic amounts of FVIIa allow appropriate thrombin production in intrinsic tenase-deficient plasmas (45) (46) (47) (48) (49) . The lack of cyclic amplification (or positive feedback) implies that FXa production is a linear function of the amount of FVIIa available. Thus restoring hemostasis in deficient plasmas necessitates high doses of FVIIa, yet thrombin production remains below normal (44, 49) . Restoring thrombin production with FX FpA follows a different strategy. Initial triggering of the clotting cascade is functional in hemophiliacs, only amplification is defective. The FX FpA cascade would rely on the same mechanisms for triggering, but would re-establish an intrinsic amplification of the signal. Initial traces of thrombin would slowly transform FX FpA into FXa, which in turn would cause more prothrombin conversion and subsequently more FX FpA activation. Thus, following an initial triggering, thrombin production through FX FpA activation would auto-amplify, once a threshold had been reached. Such cyclic amplification comprises a potential for exponential enhancement, as occurs in normal clotting cascade through the intrinsic tenase complex. A second likely advantage of the FX FpA approach would be little immunogenicity. Severe A-type hemophiliacs resist FVIII therapy because they develop antibodies against what they identify as a foreign protein. FVIIa therapy is exempt from this complication because FVIIa is normally present in hemophiliac blood. Similarly, FX FpA could be appropriate to treat hemophiliacs developing inhibitors, because FX and FpA would be normally present in treated hemophiliac blood. A third benefit of FX FpA could be its plasma half-life. Based on that of normal FX, the half-life of the FX chimera could be as long as 30 h (50), far longer than that of FVIIa (less than 3 h). Finally, and perhaps most importantly, activation and neutralization of FX FpA appeared self-controlled. FX FpA activation would occur only in the presence of thrombin (or TF-FVIIa complex), thus would be confined to the site of injury, where a large amount of thrombin is needed. Systemic activation would be constrained by the relatively slow rate of FX FpA activation by thrombin, thus limiting the risk of uncontrolled initiation. Through the intrinsic tenase complex, normal hemostasis triggers FXa production several 100-fold more efficiently, yet handles prevention of FXa and thrombin dissemination through neutralization by antithrombin. It is unlikely that introducing a comparatively slow amplification loop could saturate mechanisms that normally confine the clot at the site of injury. Consistent with this hypothesis, adding the chimera to normal plasma had no detectable effect on clot formation, contrary to therapeutic doses of FVIIa or FVIII, which both shortened the time to clot formation.
Hrachovinova et al. (17) proposed an elegant approach based on an increase of circulating procoagulant microparticles to correct hemostasis in hemophiliacs. As with FVIIa-based therapy, however, there is no cyclic amplification of thrombin production. In addition, infusion of a soluble chimera of P-selectin reduces the clotting time of wild-type mice, this lacks self-control. The combination of FXa and phospholipid vesicles (13, 14) as well as acylated-FXa, which slowly hydrolyzes to FXa in blood (15, 16) , are other therapies that effectively bypass the intrinsic tenase complex in vivo. Again, these approaches do not induce cyclic amplification of thrombin generation, and, as above, potential drawbacks result from the difficulty in controlling FXa generation, occurring slowly but continuously, out of control, and without localization at the site of injury. Finally, Kwan et al. (51) described a self-activating FX derivative in which the activation sequence was changed to that of prothrombin, and Rudolph et al. (39) prepared several variants of FX that also auto-activate. Theoretically, these FX derivatives must permit an auto-amplification of FXa production equivalent to that obtained with FX FpA . These FX derivatives have not been designed or tested for the purpose of hemophiliac treatment. Whether adding self-activating FX in intrinsic tenase-deficient plasma safely corrects hemostasis should be investigated in future studies.
